Pediatric Mononucleosis and Epstein-Barr Virus Infection Guidelines

Updated: Dec 05, 2018
  • Author: Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP; Chief Editor: Russell W Steele, MD  more...
  • Print

Guidelines Summary

Guidelines on the diagnosis, prevention, prophylaxis, and treatment of Epstein-Barr virus–related posttransplant lymphoproliferative disorders in allogeneic hematopoietic stem cell transplant patients were published in 2016 by the Sixth European Conference on Infections in Leukemia. The guidelines recommend rituximab, immunosuppression reduction, and Epstein-Barr virus–specific cytotoxic T-cell therapy as first-line treatment in these patients. Unselected donor lymphocyte infusions and chemotherapy are recommended as second-line options, while antiviral drugs are not recommended for prophylaxis, with evidence indicating that they are ineffective against latent Epstein-Barr virus. [19]